Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Ahead of G20 Summit, Global Pharma Leaders Prod PM Abe to Take Leadership in Addressing Health Challenges
June 5, 2019
- Generic Industry Calls for Support for API Purchase Cost, Revision of Gx Pricing: LDP Study Group
June 3, 2019
- JPMA Asks Govt to Buy 1.3 Billion Yen Cryo-EM Equipment to Fuel Drug Discovery
May 29, 2019
- JPWA Pushing for September Announcement of New NHI Prices
May 27, 2019
- Medipal Pres. Watanabe Elected as New JPWA Chief
May 24, 2019
- Professor Calls for More Balanced Healthcare Resource Allocation, Higher Copay for Minor Illnesses
May 24, 2019
- Hodanren Renews Call for Transparent Pricing for Kymriah
May 23, 2019
- OTC Industry Group to Up Its Efforts to Reduce “Switch Lag”
May 22, 2019
- Sales of Japan CRO Association Members Down 1.2% to 190 Billion Yen in 2018; Pharma Sales Up 2.6%
May 22, 2019
- Wholesaler Group to Set Up Own Rules for Information Provision by Autumn
May 21, 2019
- Kymriah’s 33.5 Million Yen Price Tag Favorably Received by JMA
May 16, 2019
- Payer Reps Stress Need to Revise Coverage of Drugs for Minor Illnesses; Kymriah’s Price Isn’t Necessarily too High
May 16, 2019
- Number of Contract Sales Reps Down 11.5% in FY2018: JCSOA
April 19, 2019
- GHIT Fund to Leverage Japanese Technology to Benefit Neglected Patients around the World: New CEO
April 18, 2019
- Regenerative Medicine Groups in Asia Begin Discussions towards Mutual Approval
April 15, 2019
- JPMA Not Envisioning Asia-Version EMA at This Point: Chief
April 11, 2019
- Drug Damage Watchdog Nudges Govt, Shionogi to Suspend Xofluza Sales
April 10, 2019
- Vaccine Heavyweight Prods Japan to Expedite Recommendation Process for Immunization Program, Ensure Funding
April 9, 2019
- Patient Groups Press for Emergency Import of Methotrexate amid Tight Supply
April 8, 2019
- Hodanren Calls for Transparency in Kymriah Pricing Process
April 8, 2019
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…